Medication
On:

Clozapine monitoring includes blood counts to detect neutropenia and ongoing review of physical and mental health. Services also assess constipation, weight, metabolic measures, cardiovascular symptoms and other concerns according to local protocols. Monitoring is broader…Continue Reading

Medication
On:

Serious clozapine risks include severe neutropenia, myocarditis, seizures and gastrointestinal hypomotility. Marked constipation can progress to dangerous bowel complications and should not be dismissed as a minor inconvenience. Sedation, low blood pressure and metabolic changes…Continue Reading

Medication
On:

Clinical trials established that clozapine can help some people whose schizophrenia has not responded adequately to other antipsychotics. Benefit may involve reduced psychotic symptoms, distress or disruptive illness patterns. The extent and timing of improvement…Continue Reading

Medication
On:

Clozapine binds to dopamine, serotonin, histamine, adrenergic and muscarinic receptors. Its laboratory affinity is relatively stronger at several non-D2 targets than at D2. This broad profile helps explain some effects, including sedation, postural dizziness and…Continue Reading

Medication
On:

Clozapine is an established option when schizophrenia has not responded adequately to other appropriate antipsychotic trials. Treatment resistance requires careful assessment of dose, duration, actual exposure and persistent symptoms. Apparent failure can sometimes reflect interactions…Continue Reading

Medication
On:

D2 partial agonists can provide antipsychotic benefit with a different balance of effects from conventional antagonists. Lower prolactin burden can be helpful for some people. However, akathisia, activating effects, sleep problems and weight changes remain…Continue Reading

Medication
On:

Brexpiprazole and cariprazine are D2 partial agonists with different additional pharmacological properties. Cariprazine has particularly high affinity for D3 receptors and long-lasting active metabolites. Brexpiprazole also affects serotonin and adrenergic targets. These differences mean the…Continue Reading

Medication
On:

Aripiprazole is an antipsychotic with partial agonist activity at D2 and 5-HT1A receptors and antagonist activity at 5-HT2A receptors. It is used for several indications depending on the formulation and country. Its receptor pattern differs…Continue Reading